SCHEMBL31170653

SCHEMBL31170653

Cc1ccn(C(=O)N2CCN(C(=O)OC(C)(C)C)CC2C(F)(F)F)n1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ABHD6 Q9BV23 2/20 0.43
▸ DAGLA Q9Y4D2 1/20 0.41
▸ SPR P35270 3/20 0.39
▸ PDK2 Q15119 1/20 0.38
▸ GPR119 Q8TDV5 3/20 0.38
▸ RORC P51449 1/20 0.37
▸ ROCK2 O75116 1/20 0.37
▸ SETD7 Q8WTS6 1/20 0.37
▸ USP30 Q70CQ3 1/20 0.36
▸ MEN1 O00255 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ KMT2A Q03164 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ CHRM2 P08172 1/20 0.36
▸ CHRM4 P08173 1/20 0.36
▸ CHRM1 P11229 1/20 0.36
▸ CHRM3 P20309 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31169977 0.86 SETD7 (0.47) ABHD6DAGLASPRGPR119SETD7
SCHEMBL31170689 0.84 ABHD6 (0.40) ABHD6DAGLASPRGPR119SETD7
SCHEMBL31170462 0.80 ABHD6 (0.42) ABHD6DAGLAGPR119MEN1MAPT
SCHEMBL31170385 0.75 SPR (0.44) SPRGPR119RORCSETD7
SCHEMBL31170139 0.75 SPR (0.44) SPRGPR119RORCSETD7
SCHEMBL31169853 0.73 SCN9A (0.36) —
SCHEMBL20011906 0.72 USP2 (0.42) GPR119SETD7MEN1MAPTKMT2A
SCHEMBL2013279 0.72 NOS1 (0.46) GPR119MEN1MAPTTSHRKMT2A
SCHEMBL31257360 0.71 F13A1 (0.38) ABHD6GPR119SETD7MEN1MAPT
SCHEMBL38662966 0.70 USP30 (0.44) GPR119USP30MEN1MAPTTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4712961-A2 KRAS G12S AND G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2026-03-25 — — EP disclosed
WO-2024238633-A2 KRAS G12S AND G12C INHIBITORS Mirati Therapeutics, Inc. (US) 2024-11-21 — — WO disclosed
Send feedback